Status:
COMPLETED
Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension
Lead Sponsor:
Handok Inc.
Conditions:
Essential Hypertension
Eligibility:
All Genders
19-75 years
Phase:
PHASE2
Brief Summary
A Randomized, Double-blind, Multicenter, Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypertension
Eligibility Criteria
Inclusion
- Patients who are 19 years or older / 75 years or younger on screening
- Signed informed consent
- Patients with Essential Hypertension
- Other inclusion applied
Exclusion
- Orthostatic hypertension with symptom
- Other exclusion applied
Key Trial Info
Start Date :
May 21 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2021
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT04488978
Start Date
May 21 2020
End Date
November 9 2021
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yonsei University Health System, Severance Hospital
Seoul, South Korea, 03722